Stock:

Purapharm Corporations Ltd.

1 Month H/L:

1.35 – 1.57

Stock Code:

1498.HK

52 week H/L:

0.67 – 2.00

Market Cap.:

HKD 574.051M

Listing date:

08/07/2015

Stock Outstanding:

395,897,275 shares

Listing price:

5.98

P/E (TTM):

N/A

Chairman & CEO:

Mr. Chan Yu Ling, Abraham

Dividend:

N/A

Major Shareholdes:

1. Chan Yu Ling & Man Yee Wai, Viola – 55.55%

Dividend Yield:

N/A

Business segment

Business description

Remarks

China CCMG

the group is of the five company that obtained a license from China Food and Drug Administration (CFDA) to produce and sell CCMG products in China

Revenue increased by 26.8% to HK$353.0 miilion. This segement represented approximately 53.5% of the company's total revenue.  The company attributed the increase in sales to the following factors: 1. New national standards of CCMG by PRC Government. The Chinese National Medical Products Adminstration (“NMPA”) released new rules in which the producers must comply in order to sell CCMG products in China. It is likely that consumers make purchase prior to the implementation of the new rules. The impact of the new standards to the company is unclear at this stage.

2. Another attribution to the increase in sales is the consumption of CCMG rose in the second half of 2021.

Hong Kong CCMG

Sales of CCMG products to hospitals, Chinese medicine clinics and private Chinese medicine practitioners.

Revenue increased by 11.1% to HK$162.74 miilion. This segement represented approximately 24.7% of the company's total revenue.  

The company continued to hold a leading position in providing CCMG in the Hong Kong market.

Chinese healthcare products

Sales of Chinese health care products to USA, Japan and Hong Kong markets.

Revenue decreasd by 8.9% to HK$78.10 miilion. This segement represented approximately 11.8% of the company's total revenue.  

The decrease was affected by the drop in sales in USA market. The COVID-19 pandemic in USA and subsequet measures to subdue the outbreak caused a disruption in the supply chain for raw materials as well as labour supply, both these factors contributed to the sales decline in America.

On the other hand, sales of Chinese health care products in Hong Kong was stable and recorded a slight increase of 1.6% in comparison to last year.

Nong's ® Chinese medicine clinics

Chinese medicine clinics that provide medicial services and sales of CCMG products

Revenue increased by 0.2% to HK$50.03 miilion. This segement represented approximately 7.6% of the company's total revenue.  

Downsizing of the clinic network in Hong Kong and loss recorded in mainland China clinics were factors that caused limited growth in this segment.

Plantation

Plantation and trading of raw Chinese herbs

Revenue dropped by 61.9% to HK$15.73 miilion. This segement represented approximately 2.4% of the company's total revenue.  

The loss of this segment was attributed to the non-recurring impairment loss on the biological assets as well as on the goodwill due to strucutral change of this part of the business.